I et andet klinisk forsøg blev Rasilez HCT' s virkning og sikkerhed ligeledes vurderet i 489 overvægtige, hypertensive patienter, der ikke responderede på hydrochlorthiazid 25 mg (baseline systolisk/ diastolisk blodtryk 149, 4/ 96, 8 mmHg).
In another clinical trial, the efficacy and safety of Rasilez HCT were also assessed in 489 obese hypertensive patients who did not respond to hydrochlorothiazide 25 mg (baseline systolic/ diastolic blood pressure 149.4/ 96.8 mmHg).